Recent News

• 09.15.2025 - Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.15.2025 - Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.10.2025 - CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
• 09.10.2025 - CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
• 09.03.2025 - Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
• 09.03.2025 - Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
• 08.27.2025 - Personalis to Participate in Upcoming Investor Conferences
• 08.27.2025 - Personalis to Participate in Upcoming Investor Conferences
• 08.05.2025 - Q2 2025 Personalis Earnings Conference Call
• 08.05.2025 - Q2 2025 Personalis Earnings Conference Call

Recent Filings

• 09.12.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.22.2025 - 8-K Current report
• 08.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2025 - EX-99.1 EX-99.1
• 08.05.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 08.05.2025 - 8-K Current report
• 07.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.30.2025 - 4 Statement of changes in beneficial ownership of securities